Pollen

MHI Thermal Systems to Launch 31 Models of Residential-use Air-Conditioners for the Japanese Market in 2024

Retrieved on: 
Monday, March 11, 2024

- Two types of sensors, and functions using ions and ozone provide comfort and cleanliness (S Series / SK Series)

Key Points: 
  • - Two types of sensors, and functions using ions and ozone provide comfort and cleanliness (S Series / SK Series)
    TOKYO, Mar 11, 2024 - (JCN Newswire) - Mitsubishi Heavy Industries Thermal Systems, Ltd., a part of Mitsubishi Heavy Industries (MHI) Group, will launch 31 new models of residential-use air-conditioners for the Japanese market for 2024.
  • The new models in five series will be released starting April 1.
  • Together these new models provide comfortable living spaces for diverse lifestyles.
  • In addition, the AI learns how the room cools and warms, and adjusts automatically for comfortable and energy-saving operation.

NAPIGEN, Inc. Secures U.S. Patent, Awarded USDA SBIR Grant

Retrieved on: 
Monday, March 11, 2024

The patented claims of US11920140 are directed to methods for altering the genomes of mitochondria or plastids.

Key Points: 
  • The patented claims of US11920140 are directed to methods for altering the genomes of mitochondria or plastids.
  • The mitochondria, also known as the powerhouses of cells, are critical components of plant, fungal, algal, and animal cells.
  • It is the third SBIR grant the company has received since its founding in 2016.
  • NAPIGEN, Inc. expects to complete a Series A financing this year to advance partnerships with agricultural companies to bring products to market.

ImmunoLytics: Plan Ahead for Spring Allergy Season

Retrieved on: 
Thursday, February 29, 2024

Albuquerque, NM, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Spring is just around the corner, and for approximately 81 million people, that means allergy season.

Key Points: 
  • Albuquerque, NM, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Spring is just around the corner, and for approximately 81 million people, that means allergy season.
  • If allergy sufferers also have mold sensitivity, that will exacerbate the situation.
  • To better prepare for the upcoming spring allergy season, people should test their homes to see if there is a mold issue.
  • ImmunoLytics Mold Check-Up™ costs $36 per room and is analyzed by the company’s lab team that looks for 37,000 species of mold.

Early warm weather leads to early pollen count, Western Maryland health system allergy specialist says

Retrieved on: 
Monday, February 26, 2024

Paul Mauriello, M.D., with Meritus Allergy & Asthma Specialists said he found tree pollen when checking his air sampler on Feb. 12.

Key Points: 
  • Paul Mauriello, M.D., with Meritus Allergy & Asthma Specialists said he found tree pollen when checking his air sampler on Feb. 12.
  • “It’s a couple weeks early, by my records.”
    The reason for the early pollen count has to do with the environment, he said.
  • “Just a few nights of warmer weather, you'll have enough to get going.”
    Fortunately for allergy sufferers, the snow that fell in the following days cooled off the pollen production.
  • Meritus Allergy & Asthma Specialists sees the majority of its patients related to spring pollen, Dr. Mauriello said.

Draft guideline on allergen products development for immunotherapy and allergy diagnosis in moderate to low-sized study populations

Retrieved on: 
Tuesday, March 12, 2024

16

Key Points: 
    • 16

      Guideline on allergen products development for
      immunotherapy and allergy diagnosis in moderate to lowsized study populations

      17

      Table of contents

      18

      Executive summary ..................................................................................... 3

      19

      1.

    • Specific effects ................................................................................................. 17

      14
      15

      Guideline on allergen products development for immunotherapy and allergy diagnosis
      in moderate to low-sized study populations
      EMA/CHMP/72790/2024

      Page 2/18

      53

      12.

    • Management for allergies may involve avoidance of the allergen, medications to relieve

      66

      symptoms, or allergen immunotherapy (AIT) to desensitize the immune system to the allergen.

    • 71

      Recommendations are made on the clinical development, potential study designs and safety

      72

      considerations for allergen products within the scope of the guideline.

    • Guideline on allergen products development for immunotherapy and allergy diagnosis
      in moderate to low-sized study populations
      EMA/CHMP/72790/2024

      Page 3/18

      88

      While allergen specific immunotherapy is the only known disease modifying therapy for type I allergies,

      89

      there is no such treatment available for type IV allergies.

    • 93

      Several guidelines applicable for allergen products are available (see section 3) and provide advice on

      94

      quality and clinical development according to the current knowledge.

    • Guideline on allergen products development for immunotherapy and allergy diagnosis
      in moderate to low-sized study populations
      EMA/CHMP/72790/2024

      Page 4/18

      127

      However, this guideline does not cover the indication of atopic dermatitis or asthma as these

      128

      conditions will require separate clinical trials (see Section 6).

    • 129

      In addition, the guideline does not cover medicinal allergen products manufactured using recombinant

      130

      DNA technology, synthetic peptides, DNA or RNA constructs and/or cell preparations as they differ

      131

      substantially to the allergen products as discussed above.

    • 1

      156

      ?

      Guideline on the clinical development of products for specific immunotherapy for the treatment

      157
      158

      of allergic diseases - CHMP/EWP/18504/2006
      ?

      159
      160
      161

      Guideline on Allergen Products: Production and Quality Issues EMEA/CHMP/BWP/304831/2007

      ?

      Guideline on process validation for finished products - information and data to be provided in
      regulatory submissions - EMA/CHMP/CVMP/QWP/BWP/70278/2012-Rev1, Corr.1

      Guideline on allergen products development for immunotherapy and allergy diagnosis
      in moderate to low-sized study populations
      EMA/CHMP/72790/2024

      Page 5/18

      162

      ?

      Recommendations on common regulatory approaches for allergen products - CMDh/399/2019

      163

      4.

    • In any

      199

      case, a reduced validation should include all relevant manufacturing process steps that are considered
      Guideline on allergen products development for immunotherapy and allergy diagnosis
      in moderate to low-sized study populations
      EMA/CHMP/72790/2024

      Page 6/18

      200

      product specific.

    • 290

      Diagnostic allergen products (Type I allergy)

      291

      A possible target indication is diagnosis of type I hypersensitivity (immediate-type allergy) by prick,

      292

      intracutaneous or provocation testing.

    • 298

      Guideline on allergen products development for immunotherapy and allergy diagnosis
      in moderate to low-sized study populations
      EMA/CHMP/72790/2024

      Page 9/18

      305
      306

      7.1.

    • Guideline on allergen products development for immunotherapy and allergy diagnosis
      in moderate to low-sized study populations
      EMA/CHMP/72790/2024

      Page 11/18

      377

      8.

    • Clinical development of products for AIT: Study design,
      efficacy and safety

      378

      In general, the clinical development should be performed according to current guidelines.

    • In such single trial, the suitability as a test allergen as well as the

      376

      Guideline on allergen products development for immunotherapy and allergy diagnosis
      in moderate to low-sized study populations
      EMA/CHMP/72790/2024

      Page 12/18

      415

      dose finding for the therapeutic allergen could be investigated.

    • Guideline on allergen products development for immunotherapy and allergy diagnosis
      in moderate to low-sized study populations
      EMA/CHMP/72790/2024

      Page 13/18

      454
      455

      8.2.1.

    • 493

      Guideline on allergen products development for immunotherapy and allergy diagnosis
      in moderate to low-sized study populations
      EMA/CHMP/72790/2024

      Page 15/18

      527

      In general, sensitivity and specificity of the product should be determined.

    • 540

      Guideline on allergen products development for immunotherapy and allergy diagnosis
      in moderate to low-sized study populations
      EMA/CHMP/72790/2024

      Page 16/18

      561

      10.2.

    • Guideline on allergen products development for immunotherapy and allergy diagnosis
      in moderate to low-sized study populations
      EMA/CHMP/72790/2024

      Page 17/18

      595

      4.

    • Allergol Immunopathol, 1989;

      602

      17(2):53-65

      603

      Guideline on allergen products development for immunotherapy and allergy diagnosis
      in moderate to low-sized study populations
      EMA/CHMP/72790/2024

      Page 18/18

Alen Air Purifiers are Transforming Home Health to Fight Rising Indoor Air Quality Dangers

Retrieved on: 
Thursday, March 7, 2024

The company’s education campaign focuses on pervasive health risks associated with poor indoor air quality.

Key Points: 
  • The company’s education campaign focuses on pervasive health risks associated with poor indoor air quality.
  • “The dangers of poor indoor air quality are not just invisible – they silently jeopardize our health, amplifying the risk of respiratory issues, allergies and long-term health complications,” said Alen CEO, Warburg Lee.
  • Alen air purifiers with HEPA fresh filtration capture fine particles, including ash, soot and VOCs, effectively removing them from the indoor air and reducing exposure to harmful pollutants and allergens like pollen, pet dander, and mold spores, providing symptom relief and improving overall indoor air quality.
  • Addressing these sources of indoor air pollution typically involves implementing strategies such as improving ventilation, using air purifiers with HEPA filters like Alen, and reducing or eliminating the use of products with harmful chemicals.

Global Central Vacuum System Market Outlook, 2023-2024 and 2029: Key Opportunities Driven by Growth in Demand for CVS with Hepa Filters and Smart Vaccum Systems - ResearchAndMarkets.com

Retrieved on: 
Friday, February 23, 2024

The global central vacuum systems market is highly competitive, with many vendors.

Key Points: 
  • The global central vacuum systems market is highly competitive, with many vendors.
  • Some of the major players dominating the global central vacuum systems market include Trovac, DrainVac, Nuera Air, Nilfisk Group, and Busch.
  • In Europe, the demand for central vacuum systems is experiencing an increase, driven by stringent hygiene standards in the food processing industry and concerns about air quality, and dominated the global central vacuum systems market share, accounting for over 38% in 2023.
  • Furthermore, the growth of central vacuum systems in the APAC is attributed to the APAC's expansion of manufacturing and metalworking facilities.

Mānuka Health, Global Leader in Mānuka Honey, Launches Three Product Collections Designed for Holistic Inner and Outer Wellbeing

Retrieved on: 
Thursday, March 7, 2024

AUCKLAND, N.Z., March 7, 2024 /PRNewswire/ -- Mānuka Health, a global leader in premium mānuka honey products, is excited to announce the launch of three new product collections, inclusive of the brand's first skincare range. As the first prestige beauty and wellness brand to masterfully capture the complete spectrum of benefits from raw mānuka honey, propolis, and royal jelly, these new collections present one harmonious system designed to elevate vitality, reinforce resilience, and inspire complete wellbeing.

Key Points: 
  • Mānuka Health's new collections mirrors the intricate relationship between the European Honeybee pollinating amidst the blooms of the New Zealand mānuka tree.
  • The brand harvests their raw mānuka honey from the rich soils of New Zealand with brand-owned hives that ensure the utmost purity and quality.
  • Their unparalleled potency, individually and together, supports simplicity in a daily wellbeing routine for inner harmony and outer radiance.
  • All Mānuka Health's MGO mānuka honey is certified for authenticity, sustainably sourced, GMO-free, and raw and unpasteurized for exceptional benefits.

Allegra Airways Introduces Revolutionary Nationwide Mapping Tool Providing Outdoor Enthusiasts with Real-Time Routes with Less Pollen and Less Air Pollution

Retrieved on: 
Tuesday, March 5, 2024

NEW YORK, March 5, 2024 /PRNewswire/ -- Allegra, a leading brand in allergy relief, announced today the nationwide launch of Allegra Airways, a groundbreaking navigation tool designed to help outdoor enthusiasts find real-time walking, biking, and running routes with cleaner air based on hyperlocal pollen and air pollution levels on a street-by-street basis. Recent studies show that air pollution alters the pollen structure, releasing more allergens and making pollen more "aggressive." 1,2 These allergens can likely penetrate deeper into your airways, provoking more severe allergy symptoms1,2. What's more concerning is that seasonal allergy symptoms are on the rise, with an estimated 50% of the global population expected to have an allergic disease by 2050.3

Key Points: 
  • Recent studies show that air pollution alters the pollen structure, releasing more allergens and making pollen more "aggressive."
  • "By harnessing hyperlocal data on pollen and air pollution levels, Allegra Airways guides people along cleaner routes, making an invisible problem visible and enabling people to pursue their passions outdoors with confidence."
  • Allegra Airways will debut at SXSW, a global event that sits at the intersection of innovation and culture.
  • Join the Allegra Airways community to learn more about how air pollution impacts pollen and how Allegra Airways can help you breathe easy.

Annual flower stamp issue showcases environmentally important wildflowers

Retrieved on: 
Friday, March 1, 2024

Spotted beebalm and butterfly milkweed provide food and shelter for pollinators, as well as beautiful blooms for gardens and bouquets

Key Points: 
  • Spotted beebalm and butterfly milkweed provide food and shelter for pollinators, as well as beautiful blooms for gardens and bouquets
    OTTAWA, ON, March 1, 2024 /CNW/ - Canada Post's latest stamp issue features two native wildflowers that are important sources of food for a variety of pollinators, including hummingbirds, butterflies and bees.
  • The brilliant blossoms of butterfly milkweed (Asclepias tuberosa) and spotted beebalm (Monarda punctata) become heavy with nectar and pollen, attracting hungry insects and birds.
  • Those pollinators play a crucial role in fertilizing plants, including fruit trees and other agricultural crops.
  • In Canada, spotted beebalm and butterfly milkweed are native only to certain regions of southern Ontario and southwestern Quebec.